Last reviewed · How we verify
enalapril tablets
Enalapril tablets, marketed by Istituto Auxologico Italiano, hold a position in the cardiovascular market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use for primary indications, though specific details on mechanism and revenue are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | enalapril tablets |
|---|---|
| Sponsor | Istituto Auxologico Italiano |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (PHASE2)
- Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. (PHASE4)
- Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (PHASE2)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Treating Metabolic Acidosis in Chronic Kidney Disease to Prevent Adverse Kidney and Cardiovascular Outcomes (NA)
- An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) (PHASE3)
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF. (PHASE3)
- COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- enalapril tablets CI brief — competitive landscape report
- enalapril tablets updates RSS · CI watch RSS
- Istituto Auxologico Italiano portfolio CI